Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pridopidine - Prilenia Therapeutics

Drug Profile

Pridopidine - Prilenia Therapeutics

Alternative Names: ACR-16; ASP-2314; FR-310826; Huntexil; TV-7820

Latest Information Update: 20 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeuroSearch Sweden AB
  • Developer Prilenia Therapeutics; Teva Pharmaceutical Industries
  • Class Antiparkinsonians; Antipsychotics; Neuropsychotherapeutics; Piperidines; Small molecules; Sulfones
  • Mechanism of Action Dopamine D2 receptor antagonists; Glutamate modulators; Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Parkinson's disease
  • Phase I Amyotrophic lateral sclerosis
  • Preclinical Alzheimer's disease; Eye disorders; Fragile X syndrome; Rett syndrome
  • Discontinued Huntington's disease; Schizophrenia

Most Recent Events

  • 20 Sep 2019 Phase-I clinical trials in Amyotrophic lateral sclerosis in Israel (PO) (Prilenia Therapeutics pipeline, September 2019)
  • 19 Sep 2019 Prilenia Therapeutics plans a clinical trial (the HEALEY ALS Platform trial) for Amyotrophic lateral sclerosis in USA
  • 18 Sep 2019 Prilenia plans a phase III trial for Huntington disease in 2019 (Prilenia Therapeutics pipeline, September 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top